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modulate IL-17 and IL-22 production, as
well as the expression of IL-17 receptors
on PBMCs from healthy donors in vitro.
Looking ahead
This interesting and provocative work
by Agak et al. (2014) poses many
fascinating new questions relating to
initiating events in acne pathogenesis
and mechanisms of inflammation.
Further in vivo work should determine
whether some or all of these findings
have relevance to the clinical setting,
with a view toward informing the
development of novel therapies.
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New Insights into Acne Pathogenesis:
Propionibacterium Acnes Activates the
Inflammasome
Emmanuel Contassot1 and Lars E. French1
The precise contribution of the commensal bacterium Propionibacterium acnes
(P. acnes) in the inflammatory response associated with acne vulgaris remains
controversial. In this issue Qin et al. show that P. acnes induces robust IL-1b
secretion in monocytic cells by triggering the activation of the NLRP3 inflamma-
some. In vivo, the encounter of P. acnes and macrophages in the peri-follicular
dermis could locally result in the release of substantial amounts of IL-1b and
therefore exacerbate inflammation. Such findings suggest that molecules targeting
IL-1b and/or the NLRP3 inflammasome may constitute new treatment possibilities
for acne vulgaris.
Journal of Investigative Dermatology (2014) 134, 310–313. doi:10.1038/jid.2013.505
Acne vulgaris is a common inflamma-
tory skin disease affecting B80% of
individuals at some time during their
lives (Williams et al., 2012). The dis-
ease, affecting the pilo-sebaceous unit,
is a multifactorial process involving both
endogenous and exogenous factors,
including increased sebum production,
altered follicular keratinization, inflam-
mation, and bacterial colonization of
the pilo-sebaceous unit by Propioni-
bacterium acnes (P. acnes), a common
anaerobic Gram-positive commensal of
normal skin. Increased sebum pro-
duction and follicular hyperkeratosis
are thought to be initial events leading
to a change of the pilo-sebaceous milieu
that favors the proliferation of P. acnes
See related article on pg 381
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(Kurokawa et al., 2009). Pro-inflam-
matory cytokines including interleukin-
1a (IL-1a) and tumor necrosis factor-a
(TNFa) are, among others, considered to
be responsible for the further follicular
hyperkeratinization and the inflam-
matory lesions characteristic of acne
(Gollnick, 2003; Zouboulis et al., 2005;
Kurokawa et al., 2009). Controversy
exists, however, concerning the signifi-
cance of the commensal P. acnes in the
development of acne (Kurokawa et al.,
2009), and its precise role(s) in acne
pathogenesis are still unclear. It has
been suggested that P. acnes, which loca-
lizes and proliferates preferentially in
the lipid-rich environment of the pilo-
sebaceous unit, may contribute to the
development of inflammatory lesions by
releasing chemotactic factors, by indu-
cing the secretion of IL-6 and IL-8 by
follicular keratinocytes, and by inducing
IL-1b, TNF-a, IL-8, and IL-12 by mono-
cytic cells in a Toll-like receptor 2-depen-
dent manner (Leeming et al., 1988;
Vowels et al., 1995; Bojar and Holland,
2004; Kurokawa et al., 2009). In addi-
tion, sebocytes have been suggested to
secrete IL-8 in response to P. acnes expo-
sure (Nagy et al., 2006). Despite this pro-
gress, the exact molecular mechanism(s)
by which P. acnes contributes to inflam-
mation in acne still remains incompletely
understood. In this issue, Qin et al.
provide novel evidence that P. acnes
contributes to the inflammatory response
seen in acne by triggering the activation
of the NLRP3-inflammasome in antigen-
presenting cells (APCs), subsequently
leading to enhanced IL-1b secretion.
The inflammasome is a cytoplasmic
molecular complex that can rapidly
initiate inflammation upon sensing
pathogen- and danger-associated mole-
cular patterns (PAMPs/DAMPs) by regu-
lating the secretion of caspase-1 acti-
vation-dependent cytokines including
IL-1b (Strowig et al., 2012). Several
Clinical Implications
 Concepts of the role(s) of Propionibacterium acnes in acne must now be
expanded.
 Inflammasome activation accompanies P. acnes activation of monocytes in
the skin, releasing inflammatory mediators, including interleukin-1b.
 Specific inhibitors of inflammasome-mediated inflammation may repre-
sent a new class of treatment for acne.
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Figure 1. Model of P. acnes-driven inflammasome activation in acne. Altered follicular keratinization, sebum hyperproduction, and Propionibacterium
acnes (P. acnes) colonization/growth within the pilo-sebaceous unit results in disruption of the follicular epithelium. P. acnes can then leak out of the
pilo-sebaceous unit and get into contact with myeloid cells such as macrophages, thereby triggering molecular events involved in NLRP3-inflammasome
activation, subsequent local release of bioactive IL-1b, and neutrophil-rich local inflammation. An earlier interaction between P. acnes and myeloid cells,
either by migration of the latter into the follicular space or ‘‘leakage’’ of P. acnes into the peri-follicular dermis, leading to inflammasome activation is not
excluded but remains to be demonstrated. Cat.B, cathepsin B; mtDNA, mitochondrial DNA; ROS, reactive oxygen species; TLR, Toll-like receptor.
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types of inflammasomes have been
described, the best studied to date
being the NLRP3-inflammasome. The
NLRP3-inflammasome can be activated
by a large variety of structurally distinct
DAMPs and PAMPs, and certain
bacterial toxins. The structural diversity
of NLRP3-inflammasome activators
suggests that these factors do not inte-
ract with a component of the NLRP3-
inflammasome, but that they activate it
by inducing a common upstream signal.
Several models have been proposed to
explain how such diverse signals can lead
to this selective activation (Strowig et al.,
2012). They include the gene-
ration of reactive oxygen species (ROS),
Kþ efflux, and lysosomal rupture (Stutz
et al., 2009; Jin and Flavell, 2010). Kþ
efflux and lysosomal rupture account for
NLRP3-inflammasome activation during
bacterial infection such as, for example,
infection caused by Chlamydia pneu-
moniae (He et al., 2010), Klebsiella
pneumonia (Willingham et al., 2009),
Porphyromonas gingivalis (Huang et al.,
2009), or Neisseria gonorrhoeae (Duncan
et al., 2009). In addition, it has been
shown that multiple NLRP3-inflamma-
some activators induce Ca2þ signaling,
the latter promoting mitochondrial
damage (Murakami et al., 2012). Taken
together, the stimuli activating NLRP3
generate certain signals of cellular stress
originating from the mitochondria
(Nakahira et al., 2011; Shimada et al.,
2012), referred to as signal 2, comple-
mentary to signal 1, which is provided by
TLRs and is crucial for the transcriptional
upregulation of NLRP3 and pro-IL-1b
(Bauernfeind et al., 2009).
In this issue, Qin et al. show that
P. acnes is a potent trigger of NLRP3-
inflammasome activation, resulting in
caspase-1 activation, and mature IL-1b
secretion in human monocytes. Qin
et al. (2014) demonstrate that P. acnes-
induced NLRP3-inflammasome activa-
tion involves Kþ efflux—an event
known to be required for inflammasome
activation—as evidenced by the
reduced IL-1b secretion obtained with
glibenclamide, an inhibitor of ATP-sen-
sitive Kþ channels such as P2X7. Note-
worthy, Qin et al. also demonstrate by
immunolabeling that mature caspase-1
and NLRP3 expression colocalizes with
tissue macrophages around the pilo-
sebaceous follicles in acne biopsies,
providing evidence of NLRP3-inflamma-
some activation within acne lesions.
The novel data reported by Qin et al.
suggest that the triggering of inflamma-
tion by P. acnes is dependent on access
of the bacterium to myeloid cells as
well as their ability to phagocytose the
bacteria and trigger a NLRP3-inflam-
masome-dependent innate immune
response. The exact site of uptake of
P. acnes by phagocytes is unclear to
date, but the encounter of P. acnes with
phagocytes such as macrophages or
dendritic cells may occur upon rupture
of the pilo-sebaceous unit, allowing
bacteria to spread into the environment
nearby, where they can be taken up by
dermal APCs including macrophages.
Previous reports showed that P. acnes,
when distributed in the extracellular
space recruits and can be phagocytosed
by macrophage-like cells (Nakatsuji
et al., 2008, 2011). Indeed, inflamma-
tory cells, and notably macrophages,
likely serving as sentinels, are present
in high numbers in the immediate
proximity of pilo-sebaceous follicles of
the uninvolved acne skin, as well as in
early stage inflammatory acne lesions,
but in contrast, not around the pilo-
sebaceous units of normal skin from
healthy individuals (Jeremy et al.,
2003). The uptake of bacteria by
phagocytes around the pilo-sebaceous
follicles is very likely to induce multiple
level signals involving on the one hand
nuclear factor-kB-mediated induction of
pro-IL-1b and on the other hand, signals
possibly involving mitogen-activated
protein kinase, resulting ultimately in
inflammasome activation and bioactive
IL-1b secretion (Tsai et al., 2013).
Identification of molecular events
occurring in dermal APCs upon encoun-
ter of P. acnes, notably local inflamma-
some-mediated IL-1b production, opens
avenues for the development of new
anti-inflammatory agents or to the use
of existing medications for the treatment
of severe forms of acne. Recently, clini-
cal reports have appeared suggesting
therapeutic effect of drugs targeting
IL-1b signaling in patients with auto-
inflammatory syndromes in which
acne is a symptom. This is the case for
PAPA syndrome (pyogenic arthritis, pyo-
derma gangrenosum, and acne),
SAPHO syndrome (synovitis, acne, pus-
tulosis, hyperostosis, and osteitis), and
PASH syndrome (pyoderma, acne, and
suppurative hidradenitis) (Brenner
et al., 2009; Braun-Falco et al., 2012;
Wendling et al., 2012). In these
patients, blocking IL-1 signaling has
been reported to reduce the severity of
acne symptoms. Furthermore, and in
accordance with data provided in this
issue by Qin et al. showing that either
inflammasome deficiency or IL-1b block-
ade prevents P. acnes-induced inflamma-
tory responses, recent interim results from
a phase 2 double-blind placebo-
controlled trial assessing a monoclonal
antibody to IL-1b (Gevokizumab, Xoma-
052) have shown that 0.6 mg kg1
Gevokizumab given once per month for
3 consecutive months induced a statis-
tically significant reduction in inflam-
matory lesion counts compared with
placebo in patients with moderate to
severe acne (Xoma, 2013).
Taken together, the study from Qin
et al. demonstrates that P. acnes can
induce robust IL-1b secretion from
monocytic cells in an NLRP3-dependent
manner and establish P. acnes as an
etiological factor of acne-associated
inflammation. Such findings combined
with the observation that caspase-1 and
NLRP3 are expressed in vivo in dermal
macrophages surrounding the pilo-
sebaceous follicles in acne lesions, sug-
gesting that molecules targeting IL-1b
and/or upstream events in inflam-
masome activation may provide new
treatment possibilities for acne vulgaris.
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Crossing Barriers; Restoring Barriers?
Filaggrin Protein Replacement
Takes a Bow
Alan D. Irvine1,2,3
In this issue of the Journal, Stout and colleagues report a novel and creative
approach to replacement of genetically determined absence or deficiency of
epidermal proteins. While these early data are certainly interesting, further validation
work is required to determine the utility of this approach in genodermatoses.
Journal of Investigative Dermatology (2014) 134, 313–314. doi:10.1038/jid.2013.506
One in ten Europeans carries at least one
filaggrin (FLG) loss-of-function (LOF)
mutation (Irvine and McLean, 2006).
These common variants are the stron-
gest genetic risk yet identified for atopic
dermatitis (AD), with an overall odds
ratio for AD of B4 (Rodriguez et al.,
2009). In addition to the risk of AD
posed by LOF mutations, variation in
FLG repeat numbers (10, 11, or 12
repeats; intragenic copy-number varia-
tion) also confers significant risk of
AD (Brown et al., 2012). Furthermore,
in addition to these genetically deter-
mined deficiencies in FLG produc-
tion, FLG expression is downregulated
secondarily in AD due to the disease
per se (Kezic et al., 2011), as recently
reviewed (McAleer and Irvine, 2013). In
addition to a role as an AD risk gene,
FLG LOFs are modifiers of disease
within AD. Individuals with AD who
carry a FLG LOF mutation are more
likely to develop asthma, to have more
severe and more persistent disease, to
have allergic sensitizations, and to
develop eczema herpeticum (McAleer
and Irvine, 2013).
See related article on pg 423
1Department of Paediatric Dermatology, Our Lady’s Children’s Hospital Crumlin, Dublin, Ireland;
2National Children’s Research Centre, Our Lady’s Children’s Hospital Crumlin, Dublin, Ireland and
3Clinical Medicine, Trinity College Dublin, Dublin, Ireland
Correspondence: Alan D. Irvine, Department of Paediatric Dermatology, Our Lady’s Children’s Hospital
Crumlin, Dublin 12, Ireland. E-mail: irvinea@tcd.ie
COMMENTARY
www.jidonline.org 313
